Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Paxlovid Gets Advisory Panel Support for Full FDA Approval

Paxlovid Gets Advisory Panel Support for Full FDA Approval

The FDA’S Antimicrobial Drugs Advisory Committee (ADAC) voted 16 to 1 on Thursday in favor of Pfizer’s antiviral Paxlovid (nirmatrelvir and ritonavir) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

The expert panel was overwhelmingly supportive of the FDA granting traditional approval to a five-day course of Paxlovid in adults. If the agency agrees, Paxlovid could soon become the first oral approved treatment for mild-to-moderate COVID-19.

“Besides oxygen, Paxlovid has been the single most important treatment tool in this epidemic,” and it continues to be pivotal for those who are unvaccinated, elderly, and/or immunocompromised,” said Richard Murphy, chief of infectious diseases at the Veterans Affairs White River Junction Medical Center in White River Junction, Vt.

Paxlovid, which renders SARS-CoV-2 incapable of replicating, got emergency use authorization (EUA) on Dec. 22, 2021, for patients who are at high risk for progression to severe COVID-19.

March 20, 2023


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies